Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-α-2a and peginterferon-α-2b

Drugs

Volumn 70, Issue 2, 2010, Pages 147-165

  Foster, Graham R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

General; Hepatitis C, treatment; Peginterferon alfa 2a; Peginterferon alfa 2b

Indexed keywords

ERYTHROPOIETIN; HISTIDINE; MACROGOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PRODRUG; RIBAVIRIN; URETHAN; VIRUS RNA;

ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; BINDING AFFINITY; BODY WEIGHT; CHILL; COMBINATION CHEMOTHERAPY; COVALENT BOND; DELIRIUM; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; INFECTION; INSOMNIA; IRRITABILITY; LEUKOPENIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MIXED INFECTION; MONOTHERAPY; MYALGIA; NEUTROPENIA; PATIENT CARE; PSYCHOSIS; QUALITY OF LIFE; RELAPSE; REVIEW; RNA TRANSCRIPTION; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY EXCRETION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 75749146715     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11531990-000000000-00000     Document Type: Review

References (99)

1. World Health Organization. Hepatitis C, 2004 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Accessed 2009 Apr 7]
2. Strader DB, Wright T, Thomas DL, et al. Diagnosis, man-agement, and treatment of hepatitis C. Hepatology 2004 Apr; 39 (4): 1147-1171
3. Perz JF, Armstrong GL, Farrington LA, et al. The con-tributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 Oct; 45 (4): 529-538
4. Lee CM, Hung CH, Lu SN, et al. Hepatitis C virus geno-types: clinical relevance and therapeutic implications. Chang Gung Med J 2008 Jan-Feb; 31 (1): 16-25
5. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007 Jul; 42 (7): 513-521
6. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10-12; 19 (3): 1-46
7. Nguyen MH, Keeffe EB. Prevalence and treatment of he-patitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005 Oct; 3 (10 Suppl. 2): S97-101
8. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008; 13 Suppl. 1: 3-8
9. Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004 Oct 15; 20 (8): 825-830
10. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006 Feb; 44 (2): 275-282
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347 (13): 975-982
12. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterfer-on-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2; 140 (5): 346-355
13. Jacobson IM, Brown Jr RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 Oct; 46 (4): 971-981
14. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 Jun 23; 352 (25): 2609-2617 (Pubitemid 41007847)
15. Manns MP, McHutchison JG, Gordon SC, et al. Pe-ginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22; 358 (9286): 958-965
16. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 Jun; 40 (6): 993-999
17. Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62 (3): 507-556
18. Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63 (7): 701-730
19. Perry CM, Jarvis B. Peginterferon-alpha-2a (40kD): a re-view of its use in the management of chronic hepatitis C. Drugs 2001; 61 (15): 2263-2288
20. Palumbo E. PEG-interferon alpha-2b for acute hepatitis C: a review. Mini Rev Med Chem 2007 Aug; 7 (8): 839-843
21. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000 Nov; 68 (5): 556-567
22. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009 Jan; 6 (1): 1-16
23. Veronese FM, Mero A. The impact of PEGylation on bio-logical therapies. BioDrugs 2008; 22 (5): 315-329
24. Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8 (24): 2139-2157
25. Schering-Plough Corporation. PegIntron® (peginterferon alfa-2b): full prescribing information [online]. Available from URL: http://www.pegintron.com/ peg/application/websites/pegintron-com.aspx [Accessed 2009 Dec 8]
26. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001 Mar-Apr; 12(2): 195-202
27. Roche Laboratories Inc. Pegasys® (peginterferon alfa-2a): complete product information [online]. Available from URL: http://www.rocheusa.com/ products/pegasys/pi.pdf [Accessed 2009 Dec 8]
28. Baron S, Tyring SK, Fleischmann Jr WR, et al. The inter-ferons. mechanisms of action and clinical applications. JAMA 1991 Sep 11; 266 (10): 1375-1383
29. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-281
30. Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem 2005 May-Jun; 16 (3): 518-527
31. Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003 Jul; 30 (1): 78-87
32. Shindo M, Hamada K, Morikawa T, et al. In vivo interferon system assessed by 20-50 oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatol Res 2008 Dec; 38 (12): 1213-1220
33. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007 Aug 1; 26 (3): 369-376
34. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006 Aug; 45 (2): 204-213
35. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginter-feron alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004 Aug; 9 (4): 491-497
36. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007 Oct; 14 (10): 721-729
37. Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003 Jul; 10 (4): 271-276
38. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004 Oct; 8 (39): iii-iv, 1-125
39. Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon versus standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003 Oct 1; 18 (7): 661-670
40. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 Apr; 49 (4): 1335-1374
41. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl. 1: 9-16
42. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008 Jan 1; 46 (1): 78-84
43. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009 Feb; 16 (2): 75-90
44. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pe-gylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 Dec; 40 (6): 1260-1265
45. Jensen DM, Morgan TR, Marcellin P, et al. Early identifi-cation of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatol-ogy 2006 May; 43 (5): 954-960
46. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 Jul 12; 357 (2): 124-134
47. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastro-enterology 2005 Aug; 129 (2): 522-527
48. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 Apr; 56 (4): 553-559
49. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peg-interferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Jul 22; 361: 580-593
50. Mangia A, Minerva N, Bacca D, et al. Individualized treat-ment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008 Jan; 47 (1): 43-50
51. Sporea I, Danila M, Sirli R, et al. Comparative study con-cerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis 2006 Jun; 15 (2): 125-130
52. Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated al-pha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol 2008 Jun; 23 (6): 861-866
53. Scotto G, Fazio V, Fornabaio C, et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated inter-feron-alpha-2a versus pegylated interferon-alpha-2b. Drugs 2008; 68 (6): 791-801
54. Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008 Oct; 28 (10): 623-629
55. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009 Jan; 49 (1): 22-31
56. Vispo E, Barreiro P, Rodriguez-Novoa S, et al. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther 2008; 13 (4): 511-517 (Pubitemid 352016713)
57. Silva MO. Compare trial: updated data. J Hepatol 2008 Aug; 49 (2): 288-289
58. Soriano V, Barreiro P, Martin-Carbonero L, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007 Apr-Jun; 9 (2): 99-113 (Pubitemid 47177082)
59. Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009 Oct; 50 (4): 1045-1055
60. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008 Jul; 15 (7): 475-481
61. Rumi M, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alfa2a plus ribavirin versus peginterferon-alfa2b plus ribavirin in chronic hepatitis C. Gastro-enterology. Epub 2009 Sep 17: doi: 10.1053/j.gastro0.2009. 08.071
62. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol 2008; 48 Suppl. 2: S370
63. Berak H, Kolakowska-Rzadzka A, Wasilewski M, et al. Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ri-bavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load. Hepatology 2007; 46 Suppl. 1: 385A-6A
64. Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pe-gylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006 Jun; 17 (2): 94-98
65. Craxi A, Piccinino F, Alberti A, et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE [abstract]. J Hepatol 2008; 48 Suppl. 2: S291
66. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007 Jul; 46 (1): 37-47
67. Witthoeft T, Hueppe D, John C, et al. Efficacy and safety of peginterferon alfa-2a or-2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE study. J Hepatol 2008; 48 Suppl. 2: S315
68. Thuy PT, Dat HT. Comparison between the two pe-ginterferons alfa in the treatment of chronic hepatitis C. Hepatol 2007; 46 (4 Suppl. 1): 387A-8A
69. Mauss S, Berger F, Schmutz G. Peginterferon alfa-2a versus peginterferon alfa-2b in the treatment of chronic hepatitis C. Hepatology 2004; 46 Suppl. 4: 730A
70. Vispo E, Tuma P, Medrano J, et al. Differences in antiviral activity and tolerability between pegylated interferon alpha-2a and-2b in HIV infected patients with chronic hepatitis C. J Hepatol 2009; 50 Suppl. 1: S238-S9
71. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Im-proved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008 Oct; 48 (4): 1033-1043
72. Zopf S, Herold C, Hahn EG, et al. Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Scand J Gastroenterol 2009; 44 (4): 486-490
73. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ri-bavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 Jan; 5 (1): 124-129
74. Yu ML, Dai CY, Huang JF, et al. Rapid virological re-sponse and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008 Jun; 47 (6): 1884-1893
75. Hammoud I,Sherbondy MH, Moonka D, et al. Peginterferon alpha-2b versus peginterferon alpha-2a in the treatment of chronic hepatitis C infection. Hepatology 2007; 46 Suppl. 1: 386A-7A
76. Kolakowska-Rzadzka A, Berak H, Wasilewski M, et al. Relevance between fibrosis and response to treatment with peginterferon alfa2a versus alfa2b with ribavirin in chronic hepatitis C genotype 3 patients: randomized open label study. Hepatology 2008; 48 Suppl. 1: 878A
77. Marquez-Peiro JF, Valero-Alcocer VE, Morales-Suarez-Varela MM, et al. Effectiveness of peginterferon alpha-2a or-2b plus ribavirin in naive patients with hepatitis C infection. Enferm Infec Microbiol Clin 2008 Mar; 26 (3): 135-140
78. Rizzetto M, Colombo M, Ascione A, et al. Effectiveness of hepatitis C virus treatment in real-life practice: a pro-spective observational multicenter study in Italy (PROBE). J Hepatol 2008; 48 Suppl. 2: S311
79. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009 Apr 21; 150 (8): 528-540
80. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009 May; 136 (5): 1618-1628 e2
81. Rustgi VK, Esposito S, Hamzeh FM, et al. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008 Mar 1; 27 (5): 433-440
82. Kaiser S, Lutze B, Hass HG, et al. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40Kd) plus ribavirin for 72 weeks. Hepatol 2008; 48 Suppl. 1: 1140A
83. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003 Feb 4; 138 (3): 197-207
84. Plosker GL, Keating GM. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in hepatitis C virus and HIV co-infection. Drugs 2004; 64 (24): 2823-2843
85. Zhao S, Cheng D, Liu E, et al. Peginterferon versus inter-feron in the treatment of different HCV genotype infections in HIV patients. Eur J Clin Microbiol Infect Dis 2008 Dec; 27 (12): 1183-1192
86. Crespo M, Mira JA, Pineda JA, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Che-mother 2008 Oct; 62 (4): 793-796
87. Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon (alpha)2a plus ribavirin versus pegy-lated interferon (alpha)2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Anti-microb Chemother 2009 Jun; 63 (6): 1256-1263
88. Younossi Z, Kallman J, Kincaid J. The effects of HCV in-fection and management on health-related quality of life. Hepatology 2007 Mar; 45 (3): 806-816
89. Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeco-nomics 2003; 21 (5): 341-349 (Pubitemid 36403438)
90. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004 Apr; 40 (4): 675-681
91. Nayman Alpat S, Usluer G, Yavuz H, et al. Effect of pegy-lated interferon treatments for chronic active hepatitis C on quality of life. J Chemother 2008 Feb; 20 (1): 101-105
92. Hashemi N, Rossi S, Navarro VJ, et al. Safety of pe-ginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf 2008 Nov; 7 (6): 771-781
93. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 Nov; 36(5Suppl. 1): S237-44
94. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms in-duced by antiviral therapyinchronic hepatitisC:comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26 (11): 655-662
95. Puoti M, Babudieri S, Rezza G, et al. Use of pegylated in-terferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004 Aug; 9 (4): 627-630
96. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008 Jun; 36 (3): 250-255
97. Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009 Apr 30; 360 (18): 1899-1901
98. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 Apr 30; 360 (18): 1839-50 99.
99. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009 Apr 30; 360 (18): 1827-1838